Progress has been made in the clinical management of B-cell neoplasms, although most remain ultimately incurable with current modalities. Redirecting T lymphocytes to lyse lymphoma/leukemia cells via bispecific molecules that simultaneously engage CD3 on T cells with a B-cell antigen, such as CD19, has emerged as a powerful novel concept, highlighted by the clinical success of blinatumomab (Blincyto™). Blinatumomab, however, requires continuous infusion, owing to its short circulating half-life. We report here on the preclinical development of MGD011, a bispecific DART 
Introduction
B-cell malignancies represent a heterogeneous group of disorders with varying characteristics and clinical behaviors (1) . While systemic chemotherapy is still the mainstay of treatment for B-cell malignancies, kinase inhibitors that selectively target molecules at the core of the transformation process and antibody therapy are now well established tools (2) . Among the latter category, rituximab (Rituxan ® ), a monoclonal antibody (mAb) that targets the B-cell antigen CD20, induces direct tumor cell apoptosis as well as complement-and antibody-dependent cytotoxicity (2)(3). These orthogonal mechanisms of action form the basis for therapeutic combinations that have improved outcome in advanced B-cell malignancies. Yet, approximately 20,000 patients die of lymphoma every year in the US alone.
Providing T lymphocytes (CTL) with the ability to recognize and destroy tumor cells has shown promise in advanced forms of leukemia and lymphoma. In the form of chimeric antigen receptor (CAR) T-cell therapy, such an approach requires ex vivo isolation, transduction, and reinfusion of the patient's T cells. This complexity can be overcome with bispecific antibodies that bind simultaneously to an antigen expressed by malignant B cells and an activation molecule on T lymphocytes (2) . The pan B-cell marker, CD19, has emerged as a promising antigen for targeting B-cell malignancies because of its broader expression profile and lower rate of down-regulation compared to other B-cell antigens (3) . Its expression is highly conserved in the majority of B-cell tumors (4) , with normal to high levels of expression in 80% of acute lymphoblastic leukemia (ALL), 88% of B-cell lymphomas, and all chronic lymphocytic leukemias (CLL) (5, 6) . Redirection of CTL to CD19 + leukemia cells via the bispecific T-cell engager (BiTE) blinatumomab (Blincyto™) (7) is effective in patients with B-cell malignancies whose disease did not respond to standard chemo-immunotherapies and has been approved by the US Food and Drug Administration for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL. Dual-Affinity ReTargeting (DART®) proteins are bispecific, antibody-based molecules with favorable stability, manufacturability, and potency; furthermore, a CD19 x CD3 DART protein compared favorably to a BiTE of the same pair of VH and VL sequences in redirected cytolysis assays (8, 9) . MGD011 (also known as JNJ-64052781) is another CD19 x CD3 DART protein designed to simultaneously target CD19 
Materials and Methods
DART Protein Engineering, Production, and Purification. MGD011, an Fc-bearing CD19 x CD3 DART protein, was constructed as described (11) using VL and VH sequences from humanized anti-CD19 mAb BU12 (12) and humanized anti-CD3 mAb XR32 (13) . The IgG1-derived Fc segment was modified to encode the L234A/L235A mutation to greatly reduce or eliminate FcγR and C1q binding (14) . Control molecules in which the variable domain sequences of an anti-fluorescein mAb 4-4-20 (15) replaced either of the DART protein arms (Fluo x CD3 or CD19 x Fluo) were engineered in a similar manner. The DART proteins were expressed transiently in CHO-S cells (8) and purified to greater than 99% purity using protein A and either size-exclusion chromatography (SEC) or other polishing steps. The purified DARTs have very low levels (less than 1%) of high molecular weight (HMW) protein present and have an apparent molecular weight of ~110 kDa (Figure S1A-B Statistical Analysis. In vitro assays were repeated at least three times. Nonlinear regression analyses were used to fit curves using GraphPad Prism. For in vivo studies, intergroup differences were assessed by two-way analysis of variance (ANOVA) with a Bonferroni correction and survival curve compared by logrank test. All analyses were performed using GraphPad Prism software (version 5.02). P values of ≤ 0.05 were considered statistically significant. inoculation, inhibited tumor dissemination and improved survival at all doses tested (0.16-500 µg/kg), with maximal activity at ≥20 µg/kg. A modest, albeit statistically significant effect of the CD3-targeted control DART molecule (500 µg/kg) was also observed, possibly due to micro-clustering of CD3 in vivo at such a high dose level. In the therapeutic paradigm, treatment was delayed 2 weeks after inoculation of Raji/GF cells to allow for establishment of disseminated lesions. Image data through day 46 and survival curves through study completion (day 48) are shown in Figure 4B and C. Most vehicle-treated mice met the euthanasia endpoint by the end of the second week after Raji/GF cell inoculation and all were dead by the end of week 4. A slightly longer survival was observed with 100 μg/kg of control DART protein, albeit not significantly different from the vehicle-treated group in this experiment. In contrast, the tumor burden in the animals treated with MGD011 showed a statistically significant survival at doses ≥4 μg/kg, with near complete tumor regression at 100 μg/kg. In all experiments, treatment with MGD011 at any dose level was not associated with body weight loss (data not shown).
MGD011 Demonstrates Prolonged Circulating Half-life in Cynomolgus Monkeys
Two cynomolgus monkey studies were performed ( Table S1 ). Analysis of MGD011 serum concentration-time profiles across these studies (Figure 5A-B) showed doseproportional increases in maximum serum concentration (C max ) across the entire dose range evaluated, indicating linear PK. Clearance was lower than the glomerular filtration rate for cynomolgus monkeys (~125 mL/h/kg, Table S2), as expected for a protein of this molecular size (~110 kDa), indicating that virtually no elimination occurs by renal Figure 1B) , a lower density of CD19 on cynomolgus monkey B cells (Figure S2A-B (Figure 6A-B) .
Contrary to the durable reduction in B cells, T lymphocytes recovered quickly after each infusion and reached or exceeded baseline levels prior to the next dose. Similar T-cell kinetics were observed in cynomolgus monkeys after the administration of MGD006, a CD123 x CD3 DART protein (13) , and in humans during blinatumomab infusion (18) . (Figure 6C and 6F ). An asymptomatic, transient, dose-dependent increase in circulating cytokine levels, a first-dose effect, was observed for IFN-γ (Figure 6I ), IL-6 ( Figure 6J) , and IL-10 ( Figure 6K ) and, to a lesser extent, TNF-α levels (data not shown), all occurring 2 hours following the end of the first infusion and returning to at or near baseline within 24 hours of the start of the infusion. Smaller levels of cytokine increase were noted with subsequent infusions, which were of a magnitude comparable to those observed following vehicle infusions, except IL-10, which exceeded levels of the vehicle control group in some instances. No MGD011-related changes in circulating IL-2, IL-4, or IL-5 levels were noted.
MGD011 was well tolerated in cynomolgus monkeys at all dose levels tested, with no compound-related toxicological effects, including cage-side observations, changes in body weight or food consumption, vital parameters, ophthalmology, electrocardiograms, body temperature, blood pressure, heart rate, respiration rate, neurological examinations, coagulation, or clinical chemistry (data not shown); furthermore, with the exception of the aforementioned hematological, bone marrow, and lymphoid organ changes, no other gross or microscopic pathological findings were noted (data not shown). Tumor lysis syndrome, which has been observed with blinatumomab (7), should be anticipated as another potential safety concern for MGD011 and proper preventive measures be implement to limit its consequences. Blinatumomab treatment was also associated with an increased risk of serious and/or severe neurological toxicities (7); a similar safety risk of neurological toxicities for MGD011 is therefore recognized. It should be noted, however, that no signs of neurological toxicity were observed in the MGD011 toxicology studies, although the predictive value of the cynomolgus monkey 
with respect to neurotoxicity of CD19 x CD3 bispecific interventions is unknown.
Similarly, no infection-related adverse events were observed in monkeys treated with MGD011, although 25% of patients receiving blinatumomab showed signs of infection (7) . Hence, patients should be monitored for infections and treated appropriately.
Immunogenicty remains a potential concern associated with antibody therapy. MGD011 limits this through the incorporation of humanized Fv regions and the minimal use of linkers. While immunogenicity in monkeys does not predict immunogenicity in humans, notably, only 3/40 monkeys treated with MGD011 showed an ADA response; given that MGD011 targets B lymphocytes, ADA development is expected to be low in all species.
Upregulation of activation markers, including PD-1, was observed amongst circulating 
